看多
Another Hop Target 3.05
Progenity (PROG) said Tuesday the US Patent and Trademark Office has issued a patent for assessment of preeclampsia using assays for free and dissociated placental growth factor, or PIGF.
The biotechnology company's chief scientific officer, Matthew Cooper, said the patent protection is important as the company pursues partnership opportunities to commercialize the Preecludia test.
The Preecludia rule-out test for preeclampsia has the potential to help healthcare providers evaluate patients who have signs and symptoms of possible preeclampsia, the company said.
Target : $3.05
The biotechnology company's chief scientific officer, Matthew Cooper, said the patent protection is important as the company pursues partnership opportunities to commercialize the Preecludia test.
The Preecludia rule-out test for preeclampsia has the potential to help healthcare providers evaluate patients who have signs and symptoms of possible preeclampsia, the company said.
Target : $3.05
註釋
Today交易進行
Progenity (PROG) shares were down almost 8% in Monday afternoon trading after the biotechnology company announced an agreement with various institutional investors for the buying and selling of nearly 13.3 million common stock shares in a registered direct offering at $1.50 per share.The offering, which will likely yield gross proceeds of nearly $20 million, is expected to close around Oct. 6, with proceeds due to be allocated for facilitating operations, investment in research and development and for working capital and general corporate purposes.
Lets Start From here
註釋
111% GAIN交易結束：目標達成
See you in another Trade ...
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。